What RevMed’s pancreatic cancer drug meant for one patient - Takeaways - MDSpire

What RevMed’s pancreatic cancer drug meant for one patient

  • By

  • Elaine Chen

  • Adam Feuerstein

  • Allison DeAngelis

  • June 4, 2026

  • 0 min

Share

  • 1

    Leanna Stokes was diagnosed with metastatic pancreatic cancer in 2023 and participated in a trial for daraxonrasib.

  • 2

    The presentation of data on daraxonrasib received a standing ovation from oncologists at a recent conference.

  • 3

    The podcast discusses the impact of daraxonrasib on Stokes' disease and life.

  • 4

    The episode also covers market reactions to other biotech data presented at the American Society of Clinical Oncology.

  • 5

    Listeners can subscribe to 'The Readout LOUD' podcast for updates on biotech developments.

Original Source(s)

What RevMed’s pancreatic cancer drug meant for one patient

  • by Elaine Chen, Adam Feuerstein, Allison DeAngelis

  • June 4, 2026

Related Content

Prognostic significance and model evaluation of the modified advanced lung cancer inflammation index in locally advanced resectable gastric cancer patients with neoadjuvant chemotherapy

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report

Advancing Gastrointestinal Cancer Risk Prediction With Patient-Centered Machine Learning: Machine Learning Modeling Study